

The Neural Mixed Effects Algorithm:

Leveraging Machine Learning for Pharmacokinetic Modelling

PAGE 2021 - Stuart Beal Methodology Session I



A. Janssen





 $\mathcal{D} = \{\mathbf{x}_i, \, \mathbf{y}_i\}_{i \in \mathbb{N}}, \, \mathbf{y}_i \sim \mathcal{N}(\mu_i, \, Var[\mathbf{Y}])$

Solve a (compartment) model $\mu = A(t; \mathbf{p})$ using MLE:

$$\mathcal{L}(\mathbf{p}) = \sum_{i} \ln Var[\mathbf{Y}] + \frac{(\mu - \mathbf{y}_{i})^{2}}{Var[\mathbf{Y}]}$$

How can we improve our accuracy?



 $\mathcal{D} = \{\mathbf{x}_i, \, \mathbf{y}_i\}_{i \in \mathbb{N}}, \, \mathbf{y}_i \sim \mathcal{N}(\mu_i, \, Var[\mathbf{Y}])$

Solve a (compartment) model $\mu = A(t; \mathbf{p})$ using MLE:

$$\mathcal{L}(\mathbf{p}) = \sum_{i} \ln Var[\mathbf{Y}] + \frac{(\mu - \mathbf{y}_{i})^{2}}{Var[\mathbf{Y}]}$$

How can we improve our accuracy?

1). Add population information to \mathbf{p} as a function of \mathbf{x}_i to generate $\mathrm{E}[\mathbf{p}_i]$ (Pop-PK).



 $\mathcal{D} = \{\mathbf{x}_i, \, \mathbf{y}_i\}_{i \in \mathbb{N}}, \, \mathbf{y}_i \sim \mathcal{N}(\mu_i, \, Var[\mathbf{Y}])$

Solve a (compartment) model $\mu = A(t; \mathbf{p})$ using MLE:

$$\mathcal{L}(\mathbf{p}) = \sum_{i} \ln Var[\mathbf{Y}] + \frac{(\mu - \mathbf{y}_{i})^{2}}{Var[\mathbf{Y}]}$$

How can we improve our accuracy?

1). Add population information to \mathbf{p} as a function of \mathbf{x}_i to generate $\mathrm{E}[\mathbf{p}_i]$ (Pop-PK).

2). Generate individualized parameters $\widehat{\mathbf{p}}_i$ based on measurements \mathbf{y}_i and IIV (NLME model).



• Typical PK parameters are estimated from data:

 $\mathbf{E}[\mathbf{p}_i] = f(\mathbf{x}_i; \ \theta)$

- Choosing the correct representation of $E[\mathbf{p}_i]$ is difficult.
- Based on basic functions, performing hypothesis tests for each covariate.
- Opportunity for Machine Learning (ML) based techniques.



Historical performance of ML methods

- In 1995¹: Used Neural network for direct prediction of μ_i .
- "Neural networks made peak serum concentration predictions ... with statistically less bias and comparable precision" compared to a NLME model.
- Several limitations:
 - Only predicts concentrations at specific timepoints
 - Cannot handle complex dosing schemes
 - No measure of uncertainty or IIV
- Limitations essentially hold true for all ML methods



Deep compartment models

- Chen et al. 2018²: automatic differentiation of ODE solvers.
- Instead of directly predicting μ a neural network ϕ predicts $E[\mathbf{p}_i]$:

 $\mathbf{E}[\mathbf{p}_i] = \phi(\mathbf{x}_i; w)$

 $\widehat{\mu}_i = A(t; E[\mathbf{p}_i])$

- Benefits:
 - Reliable solution at any timepoint
 - Supports any dosing scheme
 - Interpretable!



Neural mixed effects algorithm

Based on a model of IIV: $\widehat{\mathbf{p}}_i = \mathrm{E}[\mathbf{p}_i] \cdot \exp \eta_i$, $\eta_i \sim \mathcal{N}_p(\Omega)$, and measurement errors: $\widehat{\mathbf{y}}_i = \mu_i + \epsilon_i$, $\epsilon_i \sim \mathcal{N}(\sigma^2)$ the model parameters become $\Theta = [w, \Omega, \sigma^2]$.

We minimize the first order approximation of \mathcal{L} :

$$\underset{\Theta}{\operatorname{argmin}} \mathcal{L}_{FO} = \sum_{i} \ln C_{i} + \frac{(\mu_{i} - \mathbf{y}_{i})^{2}}{C_{i}}$$
$$Var[\mathbf{Y}] \approx C_{i} = G_{i}\Omega G_{i}' + H_{i}\sigma^{2}H_{i}'$$



Simulation experiment

- Based on NLME model of 119 Haemophilia A patients treated with factor VIII (FVIII) perioperatively³. Concentrations were modeled using a two compartment model.
- Covariates in PK model were weight, age, blood group, and intensity of surgical procedure.
- Concentrations were based on $\widehat{\mathbf{p}}_i$ with $\Omega = \begin{bmatrix} 0.129 & 0.043 \\ 0.043 & 0.0705 \end{bmatrix}$ and additive error $\sigma^2 = 0.04^2$.
- Single bolus dose of 1500 IU at t=0
- Simulated concentrations at t=5min, 30min and every hour until t=48.



Training the NME model

- Train on 75 simulated individuals, validate on 425.
- Training measurements were limited to t = [0.5h, 4h, 24h, 48h]
- Trained using the same covariates as in the NLME model.
- Estimated IIV on clearance and central volume parameters
- Accuracy defined as %-age of predictions within 0.05 IUmL⁻¹ of 'true' simulated concentration.



NME Simulation results





NME Simulation results





NME Simulation results



Final Accuracy:

Typical predictions: 68.5%

Individual predictions: 92%

 $\widehat{\Omega} = \begin{bmatrix} 0.126 & 0.0634 \\ 0.0634 & 0.0677 \end{bmatrix}, \ \widehat{\sigma}^2 = 0.0385^2$

True parameters:

 $\Omega = \begin{bmatrix} 0.129 & 0.043 \\ 0.043 & 0.0705 \end{bmatrix}, \ \sigma^2 = 0.04^2$



NME: Results for a typical individual





NME: Results for a typical individual





Easily transferred to more complex cases



Complex dosing example:

- t=0: 500 IU
- t=84: 1250 IU
- t=84.08: 100 IU/hr (6.67hrs)
- t=90.75: 250 IU & 120 IU/hr (18hrs)
- t=108.75: 100 IU/hr (48.25hrs)
- etc...



Test on real world dataset

- PK profiles of 65 Haemophilia A patients
- Measurements at t=[4, 24, 48]
- Individuals received a single bolus dose of 50 IUkg⁻¹ FVIII concentrate
- Covariates used: weight, age, blood group, VWF antigen levels
- Split in train (N=46) and test (N=19) set



Monitoring training





NME real world test result

- Final train accuracy: 47.6%, Test accuracy: 50.0%
- $\widehat{\Omega} = \begin{bmatrix} 0.0556 & 0.0414 \\ 0.0414 & 0.0781 \end{bmatrix}$, $\widehat{\sigma}^2 = 0.0597^2$







- NME algorithm can predict concentrations for any dosing scheme, and allows for reliable extrapolation of solution.
- Offers automated covariate implementation while also estimating IIV.
- Reduces data requirement and overfitting by using prior knowledge in the form of a compartment model.
- Model output is familiar to pharmacologists and interpretable!







Ask any questions in the Q&A chat or send me a mail at a.janssen@amsterdamumc.nl

Sponsors:

- Erasmus MC
- Sanquin Research & Sanquin Diagnostics
- Amsterdam UMC
- University Medical Center Groningen
- University Medical Center Utrecht
- Leiden University Medical Center
- Radboud UMC
- Netherlands Hemophilia Patient Society (NVHP)
- Dutch Hemophilia Treaters Society (NVHB) Dutch Society on Thrombosis and Hemostasis (NVTH)
- Bayer B.V. & CSL Behring B.V. & Sobi Benelux

Acknowledgments:

Authors: F. Leebeek, M.H. Cnossen, R. Mathtôt Symphony consortium OPTI-CLOT study group